Ark and PsiOxus sign manufacturing agreement
To support the development of colorectal cancer treatment
Ark Therapeutics Group has signed a manufacturing partnership agreement with PsiOxus Therapeutics, both based in the UK, under which Ark will provide manufacturing and related services to support the development of PsiOxus’ ColoAd1 programme for the treatment of colorectal cancer.
London-based Ark will work with Oxford-based PsiOxus in providing oncolytic adenoviral material for IV administration in toxicological and Phase I/II clinical studies, using its suspension based single use system (ATOSUS).
Financial details of the agreement were not disclosed.
Martyn Williams, chief executive of Ark, said PsiOxus will benefit from Ark’s experience in the regulatory CMC aspects of developing a gene-based medicine.
PsiOxus’ chief executive John Beadle added: ‘Of critical importance to us was to choose a manufacturing partner who had not only the relevant manufacturing know-how but also the manufacturing development capability and specific regulatory knowledge to ensure we hit our development timelines through the timely provision of material for final pre-clinical toxicology and clinical phases.’